(541) 773-1435
Fax: (541) 858-6828
2925 SISKIYOU BLVD.
MEDFORD, OR 97504

PR News

FOR IMMEDIATE RELEASE

Touchstone Interventional Pain Center Receives 2017 Best of Medford Award

Medford Award Program Honors the Achievement
MEDFORD March 2, 2017 — Touchstone Interventional Pain Center has been selected for the 2017 Best of Medford Award in the Medical – Interventional Pain Specialist category by the Medford Award Program.

Each year, the Medford Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Medford area a great place to live, work and play.

Various sources of information were gathered and analyzed to choose the winners in each category. The 2017 Medford Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the Medford Award Program and data provided by third parties.

About Medford Award Program

The Medford Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the Medford area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The Medford Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.

SOURCE: Medford Award Program

CONTACT:
Medford Award Program
Email: PublicRelations@onlineawarded.org


Medford, Oregon September 2016

Touchstone Interventional Pain Center Becomes the First in Medford, Oregon to Use New Treatment Therapy for Patients Suffering From Chronic Intractable Pain

September, 2016 – Touchstone Interventional Pain Center is the first facility in Medford, Oregon to use a new neurostimulation device designed to relieve the sensation of pain in patients suffering from chronic intractable pain. The device, known as the St. Jude Medical Axium™ Neurostimulator System for dorsal root ganglion (DRG) stimulation.

Shawn M. Sills, M.D is a Board Certified Anesthesiologist, Pain Management Specialist at Touchstone Interventional Pain Center in Medford Oregon, implanted the St. Jude Medical Axium system, which was used because the patient suffered severe (CRPS) Complex Regional Pain Syndrome, a chronic condition that effects a part of the body following and Injury or trauma.

Unlike traditional neurostimulation devices, the St. Jude Medical Axium system targets the DRG, a spinal structure densely populated with sensory nerves that transmit information to the brain via the spinal cord.
This first-of-its-kind device delivers a form of spinal stimulation that can target the specific areas of the body where pain occurs. As a result, DRG stimulation gives physicians the ability to effectively provide pain relief to patients with neuropathic conditions otherwise underserved by traditional SCS. Patients suffering from chronic lower limb pain associated with complex regional pain syndrome (CRPS) who have previously tried multiple treatment options without receiving adequate pain relief.

“This is another game changer for patients suffering chronic pain,” said Shawn Sills, MD.

According to the Institute of Medicine, chronic pain affects more than 100 million Americans, an incidence rate which outpaces heart disease, cancer and diabetes combined. Research suggests that, in total, the condition costs the American population an estimated 515 million workdays annually and generates upwards of 40 million visits to physicians each year.

“Dr Sills continues to be a leader in emerging new technologies that offer hope with superior chronic pain relief backed by clinical research for FDA approval. It is wonderful to see patients that has suffered can now have hope of a better quality of life”.

Long term data from the ACCURATE clinical trial have shown significantly more patients receiving DRG stimulation achieved meaningful pain relief and greater treatment success when compared to patients receiving traditional SCS (74.2 percent vs. 53 percent). Study findings also demonstrated patients receiving DRG stimulation reported no differences in paresthesia (tingling) intensity due to changes in body position (known as postural effects) when compared to traditional SCS. After 12-months, nearly all patients receiving DRG stimulation reported better stimulation targeting in their area of pain without extraneous paresthesia than patients receiving traditional SCS (94.5 percent vs. 61.2 percent).

About the St. Jude Medical Axium Neurostimulator System
The Axium Neurostimulator System stimulates a spinal target called the dorsal root ganglion (DRG), which contains primary sensory neurons that transmit pain signals from nerves to the brain. DRG stimulation with the Axium system has been shown to be particularly effective for treating pain in areas currently underserved by traditional SCS, such as the groin, lower leg and feet. The Axium system is approved for use in the U.S., Europe and Australia.

Media/ PR Contact: Rick Coimbra
541-773-1435 or email: rickc@touchstonepain.com

 


Painful withdrawal: Patients grapple with forced reductions in pain medications

Patient reactions are ranging from dismay to newfound hope as doctors cut back on narcotic painkiller prescriptions for chronic pain in an effort to combat addiction.

Linda Stotts, who lives in the town of Rogue River, said she has tried almost every available painkiller since rupturing disks in her back while trying to lift a desk in 1987. She has taken methadone for four years to ease her pain, but has been told she must taper off the drug until she is methadone-free in two months.

As she reduces her dose and her pain worsens, Stotts said she is contemplating suicide.

“I’m thinking about it myself. How much longer can I go on?” she asked.

Stotts, 69, said she fears she no longer will be able to care for herself and will have to move to a nursing home. She said she has been classified as a drug addict because of her painkiller use.

“I hate to think of other people and the misery they’re in,” she said.

Commonly used to help people beat addiction to heroin and other illegal street drugs, methadone is also used as a long-lasting painkiller that doesn’t produce a sudden, highly addictive euphoria.

However, it can suppress breathing and prove deadly, especially when combined with other drugs or alcohol, or if a patient is overweight. Methadone accounts for 2 percent of painkiller prescriptions but is tied to more than 30 percent of painkiller overdose deaths, according to Jackson County Health and Human Services…

Source: http://www.mailtribune.com/article/20151108/NEWS/151109770

 

Medford, Ore. — The FDA approves a new technology aimed at treating chronic lower back pain. It’s the first spinal cord stimulation system to be approved with the organization’s superiority labeling, and one Medford doctor is the first in the state to use this technology since it’s approval.

 Approved in May, electrodes are placed behind the spinal chord and their stimulation helps to block out pain. Patients are feeling relief as soon as a week post-surgery. 

“We’ve seen pain scales go from an 8 or 9 to a 2 or a 2 and a half,” Dr. Shawn Sills says. 

Dr. Sills says what makes this technology better than previous approaches is that patients don’t even feel it working, that means patients won’t have the tingling or shocking sensations that similar treatments once brought. And what really excites medical providers, is that this approach will relieve pain without the use of dangerous or addictive medications.

Source: https://kobi5.com/news/revolutionary-spinal-cord-surgery-in-medford-1133/

Press Releases:

Newsletters:

  Patient Portal  PR-News